Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.59−0.09 (-1.89%)
Close on Nov 17, 2026Market cap $63.91MP/E –Yield –
Champions Oncology revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Champions Oncology's revenue for the twelve months ending Jul 31, 2026 was $60.66M, up 6.7% year over year. For fiscal 2026 it was $59.43M, up 4.4% from the year before. Over ten years it grew 18.2% a year on average. The highest annual figure on record is $59.43M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $59.43M | +4.4% |
| FY2025 | Apr 30, 2025 | $56.94M | +13.5% |
| FY2024 | Apr 30, 2024 | $50.16M | -6.9% |
| FY2023 | Apr 30, 2023 | $53.87M | +9.7% |
| FY2022 | Apr 30, 2022 | $49.11M | +19.7% |
| FY2021 | Apr 30, 2021 | $41.04M | +27.8% |
| FY2020 | Apr 30, 2020 | $32.12M | +1007.7% |
| FY2019 | Apr 30, 2019 | $2.90M | -85.7% |
| FY2018 | Apr 30, 2018 | $20.24M | +31.3% |
| FY2017 | Apr 30, 2017 | $15.41M | +37.8% |
| FY2016 | Apr 30, 2016 | $11.18M | +26.2% |
| FY2015 | Apr 30, 2015 | $8.86M | -23.3% |
| FY2014 | Apr 30, 2014 | $11.55M | +38.8% |
| FY2013 | Apr 30, 2013 | $8.32M | +16.4% |
| FY2012 | Apr 30, 2012 | $7.15M | +3.9% |
| FY2011 | Apr 30, 2011 | $6.88M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $15.23M | +8.8% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $13.84M | +12.0% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $16.56M | -2.8% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $15.04M | +11.5% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $14.00M | -0.5% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $12.36M | -11.8% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $17.04M | +41.8% |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $13.49M | +16.6% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $14.06M | +11.9% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $14.00M | +7.1% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $12.02M | -5.9% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $11.57M | -19.0% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $12.56M | -8.6% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $13.07M | +1.5% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $12.77M | -3.2% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $14.28M | +21.2% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $13.75M | +22.1% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $12.88M | +21.9% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $13.19M | +22.0% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $11.79M | +16.5% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $11.25M | +17.9% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $10.56M | +20.8% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $10.81M | +20.0% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $10.12M | +32.7% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $9.55M | +41.7% |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $8.75M | +13.3% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $9.01M | +40.2% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $7.63M | +13.9% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | $6.74M | +8.2% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $7.72M | +56.8% |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $6.43M | +26.5% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $6.69M | +28.6% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $6.23M | +23.7% |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | $4.92M | +32.3% |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $5.08M | +42.6% |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $5.20M | +16.7% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | $5.03M | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $3.72M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $3.57M | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $4.46M | – |
See a number that looks wrong?